Literature DB >> 16545726

Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population.

Gregory R Pond1, Jeffrey H Lipton, Hans A Messner.   

Abstract

A plateau in long-term survival patterns of patients undergoing blood and marrow transplantation (BMT) from allogeneic donors is apparent, but whether their expected survival ever parallels that of the normative population is unclear. This study attempts to identify a cutoff time for classifying BMT patients as long-term survivors and compares their actual survival with the expected survival of an age- and gender-matched "normal" population. In this study, the records of 1386 patients who underwent allogeneic BMT at Princess Margaret Hospital between 1970 and 2002 were reviewed. Hazard rates (HRs), Kaplan-Meier survival estimates, and loss curves were used to propose a cutoff time classifying patients as long-term survivors. Factors predictive of overall survival and survival for long-term survivors were investigated. Actual survival for these patients was compared with the expected survival of the Canadian "normal" population. A cutoff time of 6 years post-BMT was proposed to define long-term survivors based on loss curves of hazard ratios and yearly survival statistics. The only statistically significant predictor of survival among long-term survivors was having a male donor (HR = 0.39; 95% confidence interval [CI] = 0.17-0.88). Although only 62% of patients survived the first year post-BMT, 98.5% of patients alive after 6 years survived at least another year. Almost 1/3 (31%) of the deaths in long-term survivors resulted from causes unrelated to transplantation or relapse. The observed number of deaths among BMT patients exceeded the expected number from the Canadian population; however, the difference in life expectancy decreased the longer that a patient survived. The 95% CIs for the observed/expected number of deaths cover 1, indicative of no difference, after the tenth year post-BMT. A cutoff of 6 years is proposed to define long-term survivorship after BMT. Life expectancy remained reduced compared with that of the "normal" population; however, this difference decreased the longer that a patient survived. Known risk factors of short-term survival disappeared, with only donor gender predictive of survival among long-term survivors.

Entities:  

Mesh:

Year:  2006        PMID: 16545726     DOI: 10.1016/j.bbmt.2005.11.518

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

1.  Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.

Authors:  Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

2.  Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.

Authors:  Anna Sällfors Holmqvist; Yanjun Chen; Jessica Wu; Kevin Battles; Ravi Bhatia; Liton Francisco; Lindsey Hageman; Michelle Kung; Emily Ness; Mariel Parman; Donna Salzman; Aman Wadhwa; Jeanette Falck Winther; Joseph Rosenthal; Stephen J Forman; Daniel J Weisdorf; Saro H Armenian; Mukta Arora; Smita Bhatia
Journal:  JAMA Oncol       Date:  2018-12-13       Impact factor: 31.777

Review 3.  Cause-specific late mortality after allogeneic stem cell transplantation.

Authors:  Smita Bhatia
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

5.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

Authors:  Paul J Martin; George W Counts; Frederick R Appelbaum; Stephanie J Lee; Jean E Sanders; H Joachim Deeg; Mary E D Flowers; Karen L Syrjala; John A Hansen; Rainer F Storb; Barry E Storer
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

6.  Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma.

Authors:  Jessica El-Asmar; Lisa Rybicki; Brian J Bolwell; Mohamed A Kharfan-Dabaja; Robert Dean; Betty K Hamilton; Rabi Hanna; Deepa Jagadeesh; Matt Kalaycio; Brad Pohlman; Ronald Sobecks; Brian T Hill; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-13       Impact factor: 5.742

7.  Menstrual Blood Stem Cell Transplantation in Mice Model of Acute Liver Failure: Does Gender of Recipient Affect the Outcome?

Authors:  Mina Fathi-Kazerooni; Gholamreza Tavoosidana
Journal:  Avicenna J Med Biotechnol       Date:  2019 Oct-Dec

8.  In situ buccal carcinoma in a teenager after hematopoietic stem cell transplantation: A case report.

Authors:  Yanbin Liu; Wei Yuan; Man Li; Long Cheng; Jinsuo Yang; Boya Yin; Xin Huang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.